Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs

被引:18
作者
DeAngelo, Jessica [1 ]
Jarrell, Daniel [1 ]
Cosgrove, Richard [1 ]
Camamo, James [1 ]
Edwards, Christopher [1 ]
Patanwala, Asad E. [2 ]
机构
[1] Banner Univ Med Ctr Tucson, Dept Pharm Serv, Tucson, AZ USA
[2] Univ Arizona, Dept Pharm Practice & Sci, Coll Pharm, Tucson, AZ USA
关键词
anticoagulants; warfarin; blood coagulation factors; hemorrhage; INTERNATIONAL NORMALIZED RATIO; CONSENSUS GUIDELINES; THROMBOSIS;
D O I
10.1097/MJT.0000000000000643
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Prothrombin complex concentrates (PCCs) are drug products containing varying amounts of vitamin K-dependent coagulation factors II, VII, IX, and X. The evidence comparing 3-factor PCC (3-PCC) versus 4-factor PCC (4-PCC) for warfarin reversal is conflicting. It has been hypothesized that 3-PCC may be less effective than 4-PCC because of relatively lower factor VII content. Study Question: The primary objective of this study was to compare international normalized ratio (INR) reversal between 3-PCC and 4-factor PCC (4-PCC) in warfarin-treated patients. The secondary objectives include comparing blood product use, total reversal costs, and cost-effectiveness between the groups. Study Design: This was a retrospective cohort study conducted in 2 affiliated, academic institutions in the United States. Consecutive adult patients who received 3-PCC or 4-PCC for warfarin reversal were included. Measures and Outcomes: The primary outcome was adequate INR reversal defined as a final INR <= 1.5. Secondary outcomes were the utilization of plasma, red blood cells and platelets, reversal costs, and the cost-effectiveness ratio. Results: There were 89 patients who were included in the overall cohort (3-PCC = 57, 4-PCC = 32). Adequate INR reversal occurred less commonly with 3-PCC (45.6%) compared with 4-PCC (87.5%) (P < 0.001). There was no significant difference in the proportion of patients who received plasma (32% vs. 28%, P = 0.813), red blood cells (37% vs. 47%, P = 0.377), or platelets (16% vs. 28%, P = 0.180) between the 3-PCC and 4-PCC groups, respectively. The median reversal cost of 3-PCC ($3663) was lower than 4-PCC ($5105) (P = 0.001). The cost-effective ratio favored 4-PCC ($5105/87.5% = $5834) compared with 3-PCC ($3663/45.6% = $8033). Conclusions: Four-PCC was more effective than 3-PCC with regard to INR reversal in patients taking warfarin, but blood product use was similar. Although 4-PCC is associated with increased reversal costs, it may be cost-effective in terms of INR reversal.
引用
收藏
页码:E326 / E332
页数:7
相关论文
共 19 条
  • [1] EVALUATION OF WARFARIN REVERSAL WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE COMPARED TO 3-FACTOR PROTHROMBIN COMPLEX CONCENTRATE AT A TERTIARY ACADEMIC MEDICAL CENTER
    Al-Majzoub, Omar
    Rybak, Eva
    Reardon, David P.
    Krause, Patricia
    Connors, Jean M.
    [J]. JOURNAL OF EMERGENCY MEDICINE, 2016, 50 (01) : 7 - 13
  • [2] [Anonymous], 2013, KCENTR PROTHR COMPL
  • [3] [Anonymous], 2014, PROF FACT 9 COMPL PR
  • [4] Dosing of 3-Factor Prothrombin Complex Concentrate for International Normalized Ratio Reversal
    Baggs, Jennifer H.
    Patanwala, Asad E.
    Williams, Evan M.
    Erstad, Brian L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (01) : 51 - 56
  • [5] Warfarin reversal: consensus guidelines on behalf of the Australasian Society of Thrombosis and Haemostasis
    Baker, RI
    Coughlin, PB
    Gallus, AS
    Harper, PL
    Salem, HH
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2004, 181 (09) : 492 - +
  • [6] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [7] Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x
  • [8] Gulati G, 2011, ARCH PATHOL LAB MED, V135, P490, DOI 10.1043/2009-0474-OA.1
  • [9] Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Holbrook, Anne
    Schulman, Sam
    Witt, Daniel M.
    Vandvik, Per Olav
    Fish, Jason
    Kovacs, Michael J.
    Svensson, Peter J.
    Veenstra, David L.
    Crowther, Mark
    Guyatt, Gordon H.
    [J]. CHEST, 2012, 141 (02) : E152S - E184S
  • [10] Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose
    Holland, Lorne
    Warkentin, Theodore E.
    Refaai, Majed
    Crowther, Mark A.
    Johnston, Marilyn A.
    Sarode, Ravindra
    [J]. TRANSFUSION, 2009, 49 (06) : 1171 - 1177